Incidence and physiological mechanism of carboplatin-induced electrolyte abnormality among patients with non-small cell lung cancer.
Incidence and physiological mechanism of carboplatin-induced electrolyte abnormality among patients with non-small cell lung cancer.
复制标题
非小细胞肺癌患者卡铂所致电解质异常的发生率及生理机制
DOI：
10.18632/oncotarget.12813
复制
发表时间：
2017-03-14
期刊：
影响因子：
--
通讯作者：
Fu D
中科院分区：
文献类型：
--
作者：
Ma Y;Hou L;Yu F;Lu G;Qin S;Xie R;Yang H;Wu T;Luo P;Chai L;Lv Z;Peng X;Wu C;Fu D
为了阐明卡铂与电解质异常之间的关系，对非小细胞肺癌患者的不良事件报告进行了汇总分析。从FDA不良事件报告系统（FAERS）中共检索到19901例不良事件。汇总报告比值比（ROR）和95% CI表明，与其他治疗相比，卡铂与低钠血症（汇总ROR = 1.57，95% CI 1.182.09，P = 1.99 × 10-3）和低钾血症（汇总ROR = 2.37，95% CI 1.803.10，P = 5.24 × 10-10）显著相关。此外，我们发现脱水经常伴随卡铂治疗（汇总ROR = 2.01，95% CI 1.52 - 2.66，P = 8.37 × 10-7），这可能促使过量饮水并降低血清电解质浓度。这些信息在FDA批准的药物标签中没有提到，可以帮助解释卡铂诱导电解质异常的生理机制。总之，上述结果将有助于临床管理和癌症治疗过程中危及生命的电解质失衡的及时干预。
To clarify the association between carboplatin and electrolyte abnormality, a pooled-analysis was performed with the adverse event reports of non-small cell lung cancer patients. A total of 19901 adverse events were retrieved from the FDA Adverse Event Reporting System (FAERS). Pooled reporting odds ratios (RORs) and 95% CIs suggested that carboplatin was significantly associated with hyponatremia (pooled ROR = 1.57, 95% CI 1.182.09, P = 1.99 × 10-3) and hypokalemia (pooled ROR = 2.37, 95% CI 1.803.10, P = 5.24 × 10-10) as compared to other therapies. In addition, we found that dehydration was frequently concurrent with carboplatin therapy (pooled ROR = 2.01, 95% CI 1.522.66, P = 8.37 × 10-7), which may prompt excessive water ingestion and decrease serum electrolyte concentrations. This information has not been mentioned in the FDA-approved drug label and could help explain the physiological mechanism of carboplatin-induced electrolyte abnormality. In conclusion, the above results will facilitate clinical management and prompt intervention of life-threatening electrolyte imbalance in the course of cancer treatment.